Learning Objectives
Upon completion of this activity, participants should be able to:
- Summarize new data on the efficacy and safety of approved antiviral agents for the frontline treatment of chronic HBV infection
- Discuss the efficacy of frontline treatments for HBV infection in preventing or managing HBV resistance
- Describe factors associated with long-term response to antiviral therapy in patients with chronic hepatitis B
- Compare potential switch strategies for patients failing first-line antiviral treatment for chronic HBV infection
- Recount data on HBV reactivation in carriers treated with immunomodulatory therapy
Topics covered include:
- ETV-901: Long-term Entecavir Treatment in Nucleos(t)ide-Naive Patients
- Entecavir Efficacy and Resistance in a Large Clinical Population of Nucleos(t)ide-Naive Patients
- Efficacy and Safety of Tenofovir at 96 Weeks in Treatment-Naive HBV Patients
- Week 12 On-Treatment HBsAg Level as a Predictor of Long-term Response to Peginterferon alfa-2a Therapy in HBeAg-Negative Patients
- Predictors of SVR and HBsAg Clearance Following Long-term Adefovir Treatment in HBeAg-Negative Patients
- Efficacy of Peginterferon alfa-2a in HBeAg-Positive Patients With Lamivudine Resistance
- Entecavir vs Adefovir in Patients With Lamivudine Resistance Awaiting Liver Transplantation
- Switch to Tenofovir Following Suboptimal Response to Entecavir
- Combination Entecavir Plus Tenofovir for Multidrug-Resistant HBV
- HBV Reactivation Following Rituximab Treatment
- Posttransplantation HBV Recurrence With Antiviral and/or HBIG Treatment
- Association Between Liver Fibrosis/Cirrhosis and ALT Levels
Abstract